Don’t Paint China And India With The Same Opportunity Brush, Speakers Say
This article was originally published in The Pink Sheet Daily
China's development track is more "insular" while India is looking to establish a global reach.
You may also be interested in...
Central process will doubtless attract other switches, but countries will determine whether drug is still sold from pharmacies.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.